Rhythm Biosciences (ASX:RHY) has commenced commercialisation of its flagship blood-based colorectal cancer test, ColoSTAT, following the update and renewal of its ISO15189:2022 laboratory accreditation.
The test will initially be offered as an alternative for symptomatic individuals where stool-based screening is unsuitable, unavailable, or not preferred, addressing a significant unmet clinical need.
AI-enabled pharmaceutical company Algorae Pharmaceuticals (ASX:1AI) has received the comprehensive in silico synergy predictions generated by its AlgoraeOS v2 platform, covering over 500,000 potential combinations of cannabidiol with more than 3,000 approved and investigational drugs across 170 cell lines.
4DMedical (ASX:4DX) has secured $30.2 million in funding by entering an underwriting agreement with Bell Potter Securities, ensuring the full exercise of its 4DXO listed options.
Under the agreement, any unexercised options at expiry will be subscribed by the underwriter, guaranteeing the total funding amount.
